Xstrahl would like to say a big thank you to all the participants of the SARRP User Meeting hosted by the Xstrahl Life Sciences team on August 25th, 2019, the first day of the ICRR 2019 conference. The SARRP User Meeting brought together SARRP scientists from Europe...
Side effects caused by radiation are a limiting factor to the amount of dose that can be applied to a tumor volume. A novel method to reduce side effects in radiotherapy is the use of spatial fractionation, in which a pattern of sub-millimeter beams (minibeams) is...
A leading San Antonio dermatology center has become the first in Texas to commence advanced skin cancer radiotherapy treatments using the new RADiant treatment system from Xstrahl, global leader in superficial radiotherapy devices to treat non-melanoma skin cancer and...
Glioblastoma (GB) is the most common primary malignant brain tumor in adults. The standard of care consists of maximal possible surgical resection with concomitant radiation therapy (RT) and temozolomide (TMZ). Currently the target volume delineation for RT is based...
Xstrahl would like to invite you to explore several new treatment and preclinical research advancements at the annual ASTRO meeting on September 15th-18th in Chicago. Xstrahl is launching a new image-guidance system, a sleek and streamlined way of giving clinicians a...
Bowen’s disease is a type of squamous cell carcinoma (SCC) in situ of the skin usually characterized by slow-growing, red and scaly patches of skin. Bowen’s disease can be symptomatic and can progress to invasive SCC causing morbidity and even mortality. In their...
August 26th, 2019 The new SARRP beamline pre-clinical radiation research and CT imaging platform launched at the Xstrahl booth at ICRR in Manchester, UK, August 25th-29th Xstrahl Life Science, global leader in the development of advanced X–ray systems for pre-clinical...
August 26th, 2019 Xstrahl Life Science, global leader in advanced radiation research systems, is introducing a Monte Carlo dose engine to enable comparative research work to be carried out on its Small Animal Radiation Research Platform (SARRP) system. The new...
Small animal radiotherapy research platforms such as Xstrahl's SARRP enable more precise irradiation of tumours and normal tissues in pre-clinical models of cancer. In their study “Evaluation of four different small animal radiation plans on tumour and normal tissue...
Contact Us